What Is a Subcutaneous Injection? Definition and What Research Reports

Plain-language definition

A subcutaneous injection is an injection delivered into the layer of loose connective and fatty tissue that sits directly beneath the skin and above the muscle. The needle used is typically short and fine, and the volume delivered is small. Because this tissue layer has fewer blood vessels than muscle, a substance placed there generally forms a small pocket — often called a depot — and is absorbed into the bloodstream or the lymphatic system over a period of minutes to hours rather than immediately. The abbreviation commonly seen in the literature is SC, SQ, or s.c.

This page is for educational purposes only and is not medical advice; consult a licensed physician or qualified healthcare professional for any question about medical procedures, injections, or treatment. Nothing here describes how any procedure should be performed.

The term in anatomical and pharmacokinetic terms

Anatomically, the subcutaneous space (the hypodermis) lies between the dermis and the underlying fascia and muscle. It consists of adipocytes, collagen fibres, interstitial fluid, a capillary network and initial lymphatic vessels embedded in a hyaluronan-rich extracellular matrix. In pharmacology, this space functions as an absorption compartment: an administered substance must first disperse through the interstitium, then cross either capillary walls (favoured by small molecules) or lymphatic endothelium (favoured by large molecules) before reaching systemic circulation.

Modelling work has attempted to formalise these steps. A 2021 multiphysics model of subcutaneous injection and absorption of biotherapeutics described the injection site as a porous, deformable medium and simulated drug dispersion, tissue back-pressure and uptake as coupled processes (PMID 33811278). A companion sensitivity analysis reported that tissue properties and injection parameters influenced the simulated depot shape and absorption profile, with the authors identifying which model inputs most strongly altered predicted outcomes (PMID 34080101). Related experimental work examined how biotherapeutics transported and distributed across different tissue layers after subcutaneous administration, reporting that the layer reached by the needle shaped subsequent spread (PMID 35988855).

Why route matters: the lymphatic pathway

For large biologics, the subcutaneous route is not simply a slower version of an intravenous one. Research on monoclonal antibodies reported that transport after subcutaneous injection involved substantial lymphatic uptake, meaning molecules travelled through lymph vessels and nodes before entering blood (PMID 34547346). That detour is one reason peak concentrations after subcutaneous dosing of large proteins are typically later and lower than after intravascular delivery, and it is part of why bioavailability for such molecules is often incomplete.

Subcutaneous versus intramuscular

The two routes are frequently contrasted in the literature. A 2001 study of epinephrine absorption in adults compared intramuscular and subcutaneous administration and reported differences in absorption between the two routes, with the investigators examining time to peak plasma concentration for each (PMID 11692118). Comparisons of this kind are the empirical basis for the general statement that subcutaneous tissue, being less vascular than muscle, tends to produce slower systemic uptake.

How the term is used in peptide research

In published peptide and protein studies, "subcutaneous injection" appears as a route of administration descriptor in the methods section. It tells the reader where the substance was placed, not what it was or what it did. A paper reporting that a compound was "administered subcutaneously" is making an anatomical and procedural statement; the pharmacological claims live elsewhere in the paper.

The route is common in preclinical and clinical protein research for practical reasons: many peptides and proteins are degraded in the gastrointestinal tract, and the subcutaneous depot provides sustained release without vascular access. Examples in the verified literature span very different contexts. A 2022 rodent study administered bee venom subcutaneously in Wistar rats and reported effects on blood cell counts and biochemical parameters as the study endpoints (PMID 36186094). A clinical case report on biodistribution of insulin following a massive subcutaneous insulin injection described where the hormone was distributed after an unusually large subcutaneous exposure (PMID 35283372). In dermatology, an objective assessment study followed hyaluronic acid after subcutaneous injection to characterise what happened to the material in tissue over time (PMID 29994953).

Where the term is misused

• Treated as a synonym for "safe" or "mild." The route describes placement, not risk. Studies of subcutaneous administration document local and systemic adverse events, discussed below.
• Assumed to give the same exposure as other routes. Research comparing routes reported differences in absorption between intramuscular and subcutaneous epinephrine delivery (PMID 11692118); route is not interchangeable in pharmacokinetic terms.
• Conflated with intradermal or intramuscular. These are three distinct tissue layers. Work on biotherapeutic transport reported that distribution differed by the tissue layer reached (PMID 35988855).
• Used as an implicit instruction. In marketing copy the phrase is sometimes presented as a protocol. In the scientific literature it is a methods descriptor only, and research-use-only materials are not authorised for human administration regardless of route.
• Assumed to mean complete bioavailability. Lymphatic transit of large molecules means a fraction may not reach circulation intact (PMID 34547346).

Adverse Events and Local Reactions: What Studies Report

The published literature on subcutaneous injection documents both discomfort and tissue complications. A 2019 literature review of factors influencing pain sensation at subcutaneous injection sites examined variables such as needle characteristics, injection volume, formulation properties and injection speed, and reported that multiple technical and formulation factors were associated with pain at the site (PMID 31587143). Researchers in a 2022 nursing trial compared subcutaneous injection after coolant spray across three different body regions and reported outcomes for pain, hematoma and ecchymosis, indicating that both the site and the pre-injection intervention were studied as determinants of local effects (PMID 34970741).

Infection is also described. A 2017 report on subcutaneous injection-induced cellulitis documented soft-tissue infection arising at injection sites (PMID 28612712). In a rodent context, the bee venom study reported changes in blood cells and biochemical parameters following subcutaneous administration in Wistar rats, illustrating that systemic effects are measurable after local delivery (PMID 36186094). A case report on massive subcutaneous insulin injection described the resulting biodistribution, a reminder that the depot can behave unusually at extreme exposures (PMID 35283372). None of these findings constitute guidance; they describe what investigators observed.

Procedural literature

Technique itself has a descriptive literature. A 2008 nursing standard article on subcutaneous injection technique reviewed procedural elements including site selection, needle considerations and skin handling as they were taught and debated in practice (PMID 18300658). Such articles are written for licensed clinicians operating within a scope of practice; they are summarised here only to show that the term has a formal procedural definition in health professions education.

Related terms

• Intramuscular (IM) — delivery into skeletal muscle; compared directly with the subcutaneous route in epinephrine absorption research (PMID 11692118).
• Intradermal — delivery into the dermis, a shallower layer than the hypodermis.
• Depot — the localised pocket of injected fluid from which absorption proceeds; represented explicitly in subcutaneous absorption models (PMID 33811278).
• Bioavailability — the fraction of an administered substance reaching systemic circulation intact.
• Lymphatic uptake — entry of molecules into lymph vessels rather than capillaries, reported as a major pathway for monoclonal antibodies after subcutaneous injection (PMID 34547346).
• Interstitium — the fluid-filled matrix between cells through which an injected substance must disperse (PMID 35988855).
• Cellulitis — bacterial soft-tissue infection, reported in association with subcutaneous injection sites (PMID 28612712).

What the term does not tell you

Reading "subcutaneous injection" in a study abstract establishes only the anatomical destination of the material. It does not indicate that the substance was safe, effective, approved, or appropriate outside the study context. Many peptides described in research literature are supplied as research-use-only chemicals and are not approved medicines. Regulatory approval, when it exists, attaches to a specific product, formulation and indication — not to a route of administration. Readers with clinical questions should direct them to a licensed physician.

References

• Subcutaneous Injection of Drugs: Literature Review of Factors Influencing Pain Sensation at the Injection Site (Advances in Therapy, 2019)
• Subcutaneous injection-induced cellulites (BioMedicine, 2017)
• Subcutaneous injection technique (Nursing Standard, 2008)
• Epinephrine absorption in adults: intramuscular versus subcutaneous injection (Journal of Allergy and Clinical Immunology, 2001)
• Multiphysics Modeling and Simulation of Subcutaneous Injection and Absorption of Biotherapeutics: Sensitivity Analysis (Pharmaceutical Research, 2021)
• Multiphysics Modeling and Simulation of Subcutaneous Injection and Absorption of Biotherapeutics: Model Development (Pharmaceutical Research, 2021)
• Transport and lymphatic uptake of monoclonal antibodies after subcutaneous injection (Microvascular Research, 2022)
• Transport and distribution of biotherapeutics in different tissue layers after subcutaneous injection (International Journal of Pharmaceutics, 2022)
• Subcutaneous Injection of Bee Venom in Wistar Rats: effects on blood cells and biochemical parameters (Journal of Pharmacopuncture, 2022)
• Biodistribution of Insulin Following Massive Insulin Subcutaneous Injection (Internal Medicine, 2022)
• Hyaluronic Acid After Subcutaneous Injection—An Objective Assessment (Dermatologic Surgery, 2019)
• Effects of subcutaneous injection after coolant spray on pain, hematoma, and ecchymosis in three different regions (Nursing Forum, 2022)